Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Our mission is to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. To achieve this, we have assembled an experienced leadership team and have established global operations across the pharmaceutical value chain.
The company was founded in 2003 in Buffalo, New York, and has since grown to have operations across the U.S., China, Hong Kong, Taiwan, and the U.K. In 2017, we completed our initial public offering (IPO) on NASDAQ (Nasdaq:ATNX). Our business is organized into three segments: Oncology Innovation (R&D), Commercial and Global Supply Chain. Our global operations across the three segments are shown above.
We have internalized our commercial infrastructure and supply chain, which we believe will enable us to capture greater shareholder value and minimize supply chain risk for our proprietary oncology drugs. Our US-based commercial sales and marketing team continues to grow as we prepare for the commercial launch of our oncology products, and we believe that our high potency oncology manufacturing facilities will create value by minimizing supply chain disruptions.
Our leadership team was carefully assembled to capture the global commercial market opportunities in novel drug development. Our executive officers are seasoned leaders with complementary skill sets across global pharmaceutical R&D, operations, supply chain and manufacturing, capital markets, and mergers and acquisitions. We believe we will be able to utilize this strength to create long term value for cancer patients, our employees and our shareholders. Our team is driven by the prospect of creating new paradigms in the treatment of cancer.